Drugs / IDH1R132H peptide vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03893903 | Oct 2018 → Sep 2024 | malignant glioma | German Cancer Research Center | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IDH1R132H peptide vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03893903 ↗ |
| Known as | IDH1R132H 20-mer peptide vaccine | “IDH1R132H 20-mer peptide vaccine (IDH1-vac)” PMID 35599302 ↗ May 2022 |
| Modality | Peptide | “IDH1R132H 20-mer peptide vaccine” PMID 35599302 ↗ May 2022 |
| Route | Subcutaneous | “The vaccine is applied by s.c. injection with 300 μg IDH1R132H peptide emulsified in 0.5 ml 33% DMSO / 0.5 ml Montanide® per dose.” NCT03893903 ↗ |
| Target | IDH1 | “IDH1-vac safely targets IDH1R132H in newly diagnosed astrocytomas.” PMID 35599302 ↗ May 2022 |